Group 1 - The core point of the news is that Yiming Biotech-B (01541) has seen a nearly 4% increase in stock price following the announcement of the acceptance of its clinical trial application for IMM0306S, a dual-target antibody drug for systemic lupus erythematosus (SLE) by the National Medical Products Administration (NMPA) [1] - The drug IMM0306S is a subcutaneous formulation developed based on Yiming Biotech's core product IMM0306, which is the world's first clinical-stage dual-target molecule targeting CD47 and CD20, developed using the "mAb-Trap" technology platform [1] - The acceptance of the clinical trial application marks a significant advancement in the company's innovative drug development in the field of autoimmune diseases [1] Group 2 - At the 67th American Society of Hematology (ASH) annual meeting, Yiming Biotech presented data from a Phase I/II clinical study of IMM0306 combined with lenalidomide for relapsed/refractory CD20-positive follicular lymphoma, showing an objective response rate (ORR) of 91.2% and a complete response (CR) rate of 67.6% in patients who had previously failed at least one line of anti-CD20 monoclonal antibody treatment [2] - The safety profile of the combination therapy is manageable, with no risk of cytokine release syndrome reported, providing a promising new immunotherapy strategy for this currently incurable disease with limited treatment options after relapse [2]

Group 1 - The core viewpoint of the news is that Yiming Biotech-B (01541) has made significant progress in the development of innovative drugs for autoimmune diseases, with the acceptance of the clinical trial application for its dual-target antibody IMM0306S by the National Medical Products Administration (NMPA) [1] - IMM0306S is a subcutaneous formulation developed based on Yiming Biotech's core product, IMM0306, which is the world's first clinical-stage dual-target specific molecule targeting CD47 and CD20, developed using the company's "mAb-Trap" technology platform [1] - The stock price of Yiming Biotech-B increased nearly 4%, with a current price of 6.23 HKD and a trading volume of 3.1192 million HKD [1] Group 2 - At the 67th American Society of Hematology (ASH) annual meeting, Yiming Biotech presented data from a Phase I/II clinical study of IMM0306 combined with lenalidomide for the treatment of relapsed/refractory CD20-positive follicular lymphoma, showing an objective response rate (ORR) of 91.2% and a complete response (CR) rate of 67.6% in patients who had failed at least one line of anti-CD20 monoclonal antibody treatment [2] - The safety profile of the combination therapy is manageable, with no risk of cytokine storm, providing a promising new immunotherapy strategy for this currently incurable disease with limited treatment options after relapse [2]